Acute Leukemia – Relapsed/Refractory

Genetic mutation/ target

Wild-Type TP1

IRB# 19908: A Phase ½ Galinpepimut-S in combination with Pembrolizumab

No specific mutation/ target

IRB# 1795: Phase 2 Kinase Inhibition, individualized targeted therapies

IRB# 17379: Phase 1b, study of PDR001 and/or MBG453 in combination with decitabine

IRB# 17583: Phase 2 study of CSF1R inhibitor JNJ-40346527

IRB# 18290: Phase 1b, PLX2853

IRB# 19339: Phase III, CHAM vs. HAM

IRB# 18253: Phase 1, Voruciclib

IRB# 18238: Phase 1, Ruxolitinib + Venetoclax

Post-transplant

IRB# 17577: Phase 1, AZD5991

Studies Coming Soon for no specific mutation/target:
IRB# 15588 (SMMART Trial) #20588

Cross-Disease Study for Relapsed and Refractory:
IRB# TBD
Study Coming Soon EAY131 MATCH

Key

∥ Open for Enrollment
In Development
∥ Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php

10/15/2019